Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Raymond D. Harbison is active.

Publication


Featured researches published by Raymond D. Harbison.


Biochemical Pharmacology | 1982

Hepatic glutathione and hepatotoxicity: Effects of cytochrome P-450 complexing compounds skf 525-A, l-α acetylmethadol (LAAM), norLAAM, and piperonyl butoxide

Robert C. James; Raymond D. Harbison

Four compounds forming metabolic intermediate complexes with cytochrome P-450 in vitro were studied for their effects on hepatic glutathione in the mouse. All four compounds depleted glutathione within 1-3 hr after administration. The effect was transient for piperonyl butoxide while lasting at least 24 hr for other compounds. Induction of the mixed-function oxidase system by phenobarbital had no effect on the glutathione-depleting actions of the compounds, but induction with 3-methylcholanthrene abolished the depletion seen with piperonyl butoxide and SKF 525-A. For SKF 525-A, L-alpha-acetylmethadol (LAAM) and norLAAM, the persistent lowering of glutathione was paralleled by elevations in serum glutamic-pyruvic transaminase (SGPT) activity. This depletion of glutathione and subsequent elevations in SGPT were found to be strain and species dependent for SKF 525-A, LAAM and norLAAM. Compounds which complex with cytochrome P-450 in vitro may increase drug toxicities in vivo by mechanisms other than inhibition of oxidative drug metabolism.


Mutation Research Letters | 1985

Germ-cell mutagenesis and GSH depression in reproductive tissue of the F-344 rat induced by ethyl methanesulfonate.

Christopher M. Teaf; Raymond D. Harbison; Jack B. Bishop

Sensitivity of male F-344 rats to the dominant lethal (DL) mutagenic effect of ethyl methanesulfonate (EMS) was studied in conjunction with an evaluation of EMS-induced depression of glutathione (GSH) in testis, epididymis and vas deferens. At the maximal effect, during week 3 (days 15-19 post-EMS), a dosage of 50 mg/kg caused 13.3% fetal death (FD) vs. 3.3% in controls, while 100 mg/kg caused 56.6% FD in the same interval. EMS maximally depressed GSH to 33%, 54% and 77% of control in vas, epididymis and testis respectively. The slope of the DL dose-response curve for EMS in rats shows a 3-4-fold greater sensitivity than that reported for mice. The steepness of this curve suggests that small perturbations in endogenous protective mechanisms, such as GSH depression, may exert a greater proportional effect on germ-cell mutagenesis in rats which should be more readily observable than in mice. EMS and other electrophilic toxicants may thus influence their own primary reproductive toxicity and/or that of other agents by depression of GSH in male reproductive tissue.


Journal of Toxicology and Environmental Health | 1990

Effects of selected chemicals on the glutathione status in the male reproductive system of rats

Jay Gandy; Glenn C. Millner; Hudson K. Bates; Daniel A. Casciano; Raymond D. Harbison

Previous studies have suggested a significant role for reproductive tract glutathione in protecting against chemical-induced germ-cell mutations. Therefore, a number of compounds were tested for their ability to perturb glutathione levels in the testes and epididymides as well as liver following single acute dosages to rats. Phorone (250 mg/kg), isophorone (500 mg/kg), and diethyl maleate (500 mg/kg) significantly reduced glutathione in the liver and in both reproductive organs examined. Methyl iodide (100 mg/kg), trimethyl phosphate (600 mg/kg), naphthalene (500 mg/kg), acetaminophen (1500 mg/kg), and pentachlorophenol (25 mg/kg) affected hepatic and epididymal glutathione, but had little or no effect on testicular levels. The ability of isophorone to enhance the covalent binding of tritiated ethyl methanesulfonate (3H-EMS) to spermatocytes was assessed. Perturbation of reproductive tract glutathione by isophorone treatment significantly enhanced the extent of 3H-EMS-induced binding to sperm heads. The temporal pattern of ethylations in sperm heads was consistent with the stage of sperm development known to be susceptible to ethylations by EMS. Therefore, chemical-induced lowering of glutathione in the male reproductive tract may be a mechanism for potentiation of chemical-induced germ-cell mutations.


Chemico-Biological Interactions | 1984

Evidence for the extreme overestimation of choline acetyltransferase in human sperm, human seminal plasma and rat heart: A case of mistaking carnitine acetyltransferase for choline acetyltransferase☆

Daniel R. Goodman; Felix K. Adatsi; Raymond D. Harbison

Detection of choline acetyltransferase (ChAc) in a number of non-neuronal tissues has been extremely overestimated. There are two major types of errors encountered. Type 1 error occurs when endogenous substrates (e.g. L-carnitine) are acetylated by acetyltransferase enzymes (e.g. carnitine acetyltransferase ( CarAc ) ) yielding an acetylated product mistaken for acetylcholine (AcCh). In the past, human sperm and human seminal plasma putative ChAc activity has been extremely overestimated due to Type 1 error. This study demonstrates (1) an endogenous acetyltransferase and substrate activity in human sperm and human seminal plasma forming an acetylated product that is not AcCh but probably acetylcarnitine ( AcCar ); (2) that the addition of 5 mM choline substrate does not significantly increase acetyltransferase activity; (3) that boiled seminal plasma contains an endogenous acetyltransferase substrate which is not choline, but probably L-carnitine. Type 2 error occurs when endogenous carnitine acetyltransferase synthesizes true AcCh, resulting in mistaken evidence for ChAc. This is demonstrated by the fact that the choline substrate Km-value for the neuronal or true ChAc from mouse brain is 0.73 +/- 0.06 mM while the Km-value of choline substrate for purified CarAc from pigeon breast muscle is 108 +/- 4 mM. Type 2 error has occurred for the estimation of putative ChAc in rat heart. The rat heart ChAc was measured in previous studies utilizing a concentration of 30 mM choline substrate. While saturation of neuronal ChAc is observed at 2-5 mM choline, saturation of the rat heart CarAc enzyme is not reached until over 800 mM. Purified CarAc significantly synthesizes AcCh at 30 mM choline. Thus, putative ChAc has been greatly overestimated in the scientific literature for mammalian sperm, human seminal plasma and rat heart.


Teratogenesis Carcinogenesis and Mutagenesis | 1983

Perturbation of α-aminoisobutyric acid transport in human placental membranes: Direct effects by HgCl2, CH3HgCl, and CdCl2

Daniel R. Goodman; Michael E. Fant; Raymond D. Harbison

Mercuric chloride, methylmercuric chloride, and cadmium chloride directly affect the human placental syncytiotrophoblast microvillous membrane. These heavy metals alter the facilitated diffusion of alpha-aminoisobutyric acid (AIB) into vesicles of this membrane in microM concentrations. Mercuric chloride abolishes temporal kinetics of AIB transport, inducing an initial increase in AIB transport (27% at 100 microM) but subsequently lowering equilibrium values when compared to equilibrium time points in control. Methylmercuric chloride and cadmium chloride inhibited the initial rate of AIB transport (40% and 21%, respectively, at 200 microM), but did not affect the equilibrium value of AIB transported when compared to equilibrium levels in control. These effects were concentration dependent. Methylmercuric chloride was more potent in inhibiting AIB transport than cadmium chloride. Methylmercuric chloride and cadmium chloride effects on AIB transport were observed with minimal preincubation with placental vesicles. However, preincubation was necessary for mercuric chloride-induced perturbation of AIB transport. Cysteine protects against mercuric chloride- and methylmercuric chloride-induced effects on AIB transport but did not reverse these perturbations. Mercury- and cadmium-induced placental membrane toxicity result from interactions of these heavy metals with the placental plasma membranes.


Drug and Chemical Toxicology | 1984

Cocaine-Induced Hepatotoxicity: Lipid Peroxidation as a Possible Mechanism

Christopher M. Teaf; Richard W. Freeman; Raymond D. Harbison

In vitro experiments with hepatic washed microsomal preparations showed that malondialdehyde (MDA) formation was increased in a time- and concentration-dependent manner using COC or NC as the substrate. Though 1 mM COC or NC inhibited MDA formation, significant elevations were observed for 100, 10 or 1 microM concentrations. NC at 10 microM after a 30 minute incubation produced a 34% decrease in hepatic microsomal cytochrome P450 whereas 1 mM NC had no such effect. MDA formation in vivo, measured as total absorbance at 535 nm per gram liver, was found to be maximal 4 hours after 40 mg/kg NC ip. Elevations of serum transaminase (SGPT) however were not found until 6 hours after NC. We conclude from these studies that COC and NC induce lipid peroxidation in the liver of PB-pretreated Swiss-origin mice and that peroxidative attack may be a mechanism for hepatotoxicity of these compounds.


Toxicology and Applied Pharmacology | 1988

Antagonism of bromobenzene-induced hepatotoxicity by the α-adrenergic blocking agents, phentolamine and idazoxan

Brent D. Kerger; Jay Gandy; Thomas J. Bucci; Stephen M. Roberts; Raymond D. Harbison; Robert C. James

The coadministration of phentolamine, an alpha-adrenoreceptor antagonist, was found to be effective in antagonizing the hepatotoxicity produced by bromobenzene in B6C3F1 mice. Multiple doses of phentolamine, administered in dosages of 10 mg/kg, attenuated almost completely the acute lethality resulting from a 0.5 ml/kg dosage of bromobenzene. Consistent with this decline in lethality, the coadministration of phentolamine significantly altered the magnitude of hepatocellular necrosis, the elevation of serum alanine aminotransferase activity, and the glutathione depression normally produced by this dose of bromobenzene. These protective effects were not limited to phentolamine. Idazoxan, an adrenergic antagonist more specific for alpha 2-receptors, was equally effective in antagonizing the bromobenzene-induced hepatotoxicity. Measurements of serum catecholamine levels revealed that the administration of hepatotoxic doses of bromobenzene elevates serum epinephrine levels. Furthermore, the phentolamine antagonism of the bromobenzene hepatotoxicity could be correlated to elevated serum epinephrine levels in both a temporal and dose-dependent manner. Although the mechanism of the phentolamine antagonism remains to be established, one promising hypothesis involves its prevention of an epinephrine-mediated compromise in the glutathione-dependent detoxification of bromobenzene.


Journal of Toxicology and Environmental Health | 1982

Role of biotransformation in the potentiation of halocarbon hepatotoxicity by 2,5-hexanedione.

James D. Jernigan; Raymond D. Harbison

2,5-Hexanedione (2,5-HD) pretreatment potentiated CHCl3-induced hepatotoxicity. 2,5-HD significantly increased hepatic cytochrome P-450, NADPH cytochrome c reductase, aniline hydroxylation, p-nitroanisole O-demethylation, and aminopyrine N-demethylation in both male and female mice. 2,5-HD pretreatment potentiated CHCl3-induced centrilobular necrosis and increased serum alanine amino transferase (ALT) activity by 20 times more than CHCl3 alone. Similarly, 2,5-HD pretreatment potentiated CDCl3-induced hepatotoxicity as well as CCl4-induced hepatotoxicity in male mice, but did not potentiate trichloroethylene-, 1,1,2-trichloroethane-, or perchloroethylene-induced hepatotoxicity. In female mice, 2,5-HD pretreatment potentiated CHCl3- and CDCl3-induced hepatotoxicity as well as trichloroethylene-, 1,1,2-trichloroethane-, and carbon tetrachloride-induced hepatotoxicity, but not perchloroethylene-induced hepatotoxicity. 2,5-HD pretreatment had no preferential effect on either CHCl3- or CDCl3-induced hepatotoxicity in females. However, phenobarbital pretreatment did differentiate CHCl3- and CDCl3-induced hepatotoxicity in females. 2,5-HD-induced potentiation of halocarbon hepatotoxicity is sex dependent.


Toxicology and Applied Pharmacology | 1988

Antagonism of bromobenzene-induced hepatotoxicity by phentolamine: Evidence for a metabolism-independent intervention

Brent D. Kerger; Stephen M. Roberts; Jack A. Hinson; Jay Gandy; Raymond D. Harbison; Robert C. James

A previous study has revealed that phentolamine markedly antagonizes the bromobenzene-induced hepatotoxicity and lethality in B6C3F1 mice. One potential mechanism by which phentolamine may diminish the bromobenzene-induced hepatotoxicity is by a direct or indirect interference with the metabolism of bromobenzene to toxic metabolites. In the present study, phentolamine cotreatment failed to alter the elimination of bromobenzene from serum or the distribution of bromobenzene to liver. This suggests that phentolamine cotreatment does not indirectly interfere with bromobenzene bioactivation secondary to changes in bromobenzene absorption, distribution, or elimination. Further, a phentolamine concentration 10- to 20-fold greater than those measured in vivo failed to alter the in vitro metabolism of bromobenzene to its ortho- and para-phenolic metabolites. It is believed that para-bromophenol represents the rearrangement product of the hepatotoxic 3,4-epoxide and that ortho-bromophenol is a product of the nonhepatotoxic 2,3-epoxide pathway. Thus, it appears that phentolamine does not antagonize bromobenzene-induced hepatotoxicity by inhibiting the formation of hepatotoxic intermediates, nor by enhancing metabolism via the nonhepatotoxic pathway. On the basis of these studies, we conclude that phentolamine antagonism of bromobenzene-induced hepatotoxicity occurs through a mechanism independent of bromobenzene bioactivation.


Toxicology | 1988

Effects of piperonyl butoxide on halothane hepatotoxicity and metabolism in the hyperthyroid rat

Adaline C. Smith; Stephen M. Roberts; Lawrence M. Berman; Raymond D. Harbison; Robert C. James

A series of experiments were conducted to examine the potential role of phase I metabolism in halothane-induced liver injury in the hyperthyroid rat. The metabolism of halothane was determined in both hyperthyroid (triiodothyronine, 3 mg/kg per day, for 6 days) and euthyroid rats and in animals pre-treated with the cytochrome P-450 inhibitor piperonyl butoxide (75-100 mg/kg, i.p.). It was found that the hyperthyroid state, which is associated with a substantial increase in sensitivity to the hepatotoxic effects of halothane, decreases both oxidative and reductive routes of halothane metabolism in the rat. The production of trifluoroacetic acid (TFA), an oxidative metabolite, as well as that of chlorodifluoroethylene (CDF) and chlorotrifluoroethane (CTF), 2 reductive metabolites, was significantly reduced in hyperthyroid animals. Consistent with these findings serum and urinary bromide levels resulting from the formation of TFA, CDF or CTF were significantly reduced. The only route of halothane metabolism significantly increased by the hyperthyroid condition was the defluorination of halothane. Piperonyl butoxide administration did not render euthyroid animals sensitive to the halothane-induced hepatotoxicity and had no effect on the defluorination of halothane in euthyroid animals. However, piperonyl butoxide markedly increased the hepatotoxicity of halothane in hyperthyroid rats and, except for a modest increase in debromination reactions, decreased all measured indices of halothane metabolism including the defluorination of halothane. Thus, none of the observed changes in halothane metabolism produced by triiodothyronine or piperonyl butoxide treatment could be consistently correlated to the increases in hepatotoxicity linked to these 2 treatments. Based on these studies we suggest that the halothane hepatotoxicity induced in the hyperthyroid rat results from effects produced by either the parent compound or an as yet unidentified metabolite. In addition, these studies further demonstrate that considerable mechanistic differences exist for halothane-induced hepatotoxicity when comparing euthyroid and hyperthyroid animal models.

Collaboration


Dive into the Raymond D. Harbison's collaboration.

Top Co-Authors

Avatar

Robert C. James

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Christopher M. Teaf

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Jay Gandy

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Richard W. Freeman

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Antony R. Shoaf

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Brent D. Kerger

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Daniel R. Goodman

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Jack B. Bishop

National Center for Toxicological Research

View shared research outputs
Top Co-Authors

Avatar

Scott Jarmer

University of Arkansas for Medical Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge